Genomics Commercialization Avellino has commercialized genomic analytics and diagnostics across multiple markets (US, Korea, Japan) and operates a CLIA-certified lab testing millions, indicating a strong sales base for expanding genetic testing services and associated data insights.

Eye Health Focus With a specialization in ophthalmology genetics, eye disease prediction and progression prevention, there is a clear opportunity to upsell advanced ocular genomics analytics, targeted diagnostics, and personalized treatment pathways to eye care providers and clinics.

Strategic Partnerships Global operations in Silicon Valley, Korea, Japan and the UK plus a broad healthcare reach suggest potential to partner with regional pharma, contract research organizations, and health systems seeking scalable AI-powered genomic insights.

AI Driven Offerings Dedicated AI and machine learning driven discovery engines enable commercialization of predictive genomics, polygenic risk analyses, and early oncology detection, presenting cross-sell opportunities to biotech firms and biopharma seeking data-driven R&D acceleration.

Laboratory Scale A high-volume testing footprint (over four million infectious disease tests) and a robust CLIA-certified lab infrastructure indicate capabilities to sell managed services, data processing, and cloud-based analytics platforms to labs and healthcare networks seeking reliability and scale.